Insider Selling: Guardant Health (NASDAQ:GH) CFO Sells 2,000 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) CFO Michael Brian Bell sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $128.62, for a total transaction of $257,240.00. Following the completion of the transaction, the chief financial officer owned 47,509 shares of the company’s stock, valued at approximately $6,110,607.58. The trade was a 4.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michael Brian Bell also recently made the following trade(s):

• On Monday, March 16th, Michael Brian Bell sold 3,000 shares of Guardant Health stock. The stock was sold at an average price of $87.04, for a total transaction of $261,120.00.

Guardant Health Price Performance

NASDAQ GH traded down $0.72 during mid-day trading on Monday, reaching $124.89. The stock had a trading volume of 2,213,881 shares, compared to its average volume of 2,140,162. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $134.28. The stock has a market cap of $16.56 billion, a PE ratio of -36.84 and a beta of 1.61. The company has a fifty day moving average price of $99.39 and a 200 day moving average price of $101.12.

Institutional Investors Weigh In On Guardant Health

Large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC grew its position in shares of Guardant Health by 87.5% during the 1st quarter. Perceptive Advisors LLC now owns 300,000 shares of the company’s stock valued at $27,711,000 after acquiring an additional 140,000 shares during the period. BankChampaign National Association bought a new stake in shares of Guardant Health during the 1st quarter valued at $809,000. Western Wealth Management LLC bought a new stake in shares of Guardant Health during the 1st quarter valued at $125,000. Hamilton Wealth LLC grew its position in shares of Guardant Health by 103.0% during the 1st quarter. Hamilton Wealth LLC now owns 76,700 shares of the company’s stock valued at $7,085,000 after acquiring an additional 38,916 shares during the period. Finally, Edgestream Partners L.P. grew its position in shares of Guardant Health by 321.6% during the 1st quarter. Edgestream Partners L.P. now owns 32,257 shares of the company’s stock valued at $2,980,000 after acquiring an additional 24,606 shares during the period. Institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

GH has been the subject of a number of recent analyst reports. Raymond James Financial restated an “outperform” rating and issued a $129.00 price objective on shares of Guardant Health in a report on Monday, February 23rd. Leerink Partners boosted their price objective on shares of Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a report on Friday, February 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Barclays boosted their price objective on shares of Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, BTIG Research set a $160.00 price objective on shares of Guardant Health and gave the stock a “buy” rating in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $139.80.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.